

# BioMime Aura™ TECHNICAL SPECIFICATIONS

## STENT

Stent Material	: Cobalt Chromium (L605)
Strut Thickness	: 65µm (0.065mm or 0.026")
Stent Diameter (mm)	: 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00, 4.50
Stent Length (mm)	: 8, 13, 16, 19, 24, 29, 32, 37, 40, 44, 48
Mean Recoil	: 3.38%
Mean Foreshortening	: 0.29%

## DRUG/POLYMER

Drug	: Sirolimus
Equivalent Drug Dose	: 1.25 µg/ mm <sup>2</sup>
Polymer	: Biodegradable & Biocompatible (PLLA + PLGA)

## DELIVERY SYSTEM

Delivery System	: Rapid Exchange
Nominal Pressure	: 9 atm (Refer IFU)
Rated Burst Pressure	: Rated Burst Pressure: 14/16 atm*

\*RBP 14 atm for 4.50 mm diameter, all lengths.

\*RBP 14 atm for all diameter with length >40mm. (Refer IFU for more details)

Balloon Overhang	: ≤ 0.5 mm
Shaft Outer Diameter	: Proximal: 2.13 F Distal: 2.7 F (Refer IFU for more details)

Radiopaque Markers	: Two Platinum / Iridium Markers
Usable Catheter Length	: 142 cm (Refer IFU for more details)
Guide Catheter Compatibility	: 5F (Min. I. D. 0.056" / 1.42 mm)
Tip Entry Profile	: 0.016"

Crossing Profile	Stent Diameter	Crossing Profile
	2.00 mm	0.83mm/0.033"
	2.25 mm	0.85mm/0.033"
	2.50 mm	0.91mm/0.036"
	2.75 mm	0.98mm/0.039"
	3.00 mm	0.99mm/0.039"
	3.50 mm	1.06mm/0.042"
	4.00 mm	1.16mm/0.046"
	4.50 mm	1.19mm/0.047"

Max. Guidewire	: 0.014" (0.36)
----------------	-----------------

# BioMime Aura™ ORDERING INFORMATION

Dia/Length	8 mm	13 mm	16 mm	19 mm	24 mm	29 mm
2.00 mm	-	BIA20013	BIA20016	BIA20019	BIA20024	BIA20029
2.25 mm	BIA22508	BIA22513	BIA22516	BIA22519	BIA22524	BIA22529
2.50 mm	BIA25008	BIA25013	BIA25016	BIA25019	BIA25024	BIA25029
2.75 mm	BIA27508	BIA27513	BIA27516	BIA27519	BIA27524	BIA27529
3.00 mm	BIA30008	BIA30013	BIA30016	BIA30019	BIA30024	BIA30029
3.50 mm	BIA35008	BIA35013	BIA35016	BIA35019	BIA35024	BIA35029
4.00 mm	BIA40008	BIA40013	BIA40016	BIA40019	BIA40024	BIA40029
4.50 mm	BIA45008	BIA45013	BIA45016	BIA45019	BIA45024	BIA45029

Dia/Length	32 mm	37 mm	40 mm	44 mm	48 mm
2.00 mm	BIA20032	BIA20037	BIA20040	BIA20044	BIA20048
2.25 mm	BIA22532	BIA22537	BIA22540	BIA22544	BIA22548
2.50 mm	BIA25032	BIA25037	BIA25040	BIA25044	BIA25048
2.75 mm	BIA27532	BIA27537	BIA27540	BIA27544	BIA27548
3.00 mm	BIA30032	BIA30037	BIA30040	BIA30044	BIA30048
3.50 mm	BIA35032	BIA35037	BIA35040	BIA35044	BIA35048
4.00 mm	BIA40032	BIA40037	BIA40040	BIA40044	BIA40048
4.50 mm	BIA45032	BIA45037	BIA45040	BIA45044	BIA45048

Contact your country local Meril sales representative for availability of sizes highlighted in yellow

BioMime Aura™ is a registered trademark of Meril Life Sciences Pvt. Ltd.



More to Life

### Manufacturer:

**Meril Life Sciences Pvt. Ltd.**  
Survey No. 135/139, Bilakhia House,  
Muktanand Marg, Chala, Vapi - 396 191.  
Gujarat, India.  
T +91 260 240 8000

### Subsidiary companies:

**Meril Life Sciences Pvt. Ltd.**  
301, A-Wing, Business Square,  
Chakala, Andheri Kurla Road,  
Andheri East, Mumbai 400 093  
T +91 22 39350700  
F +91 22 39350777

### Meril, Inc.

2436 Emrick Boulevard,  
Bethlehem, PA 18020  
T +610 500 2080  
F +610 317 1672

### Meril South America

Doc Med LTDA  
Al. dos Tupiniquins,  
1079 - Cep: 04077-003 - Moema,  
Sao Paulo, Brazil.  
T +55 11 3624 5935  
F +55 11 3624 5936

### Meril GmbH.

Bornheimer Strasse 135-137,  
D-53119 Bonn,  
Germany.  
T +49 228 7100 4000  
F +49 228 7100 4001

### Meril Tibbi Cihazlar

Meril Tibbi Cihazlar İmalat ve Ticaret A.Ş.  
İçerenköy Mah. Çetinkaya Sok.  
Prestij Plaza No:28  
Kat:4 Ataşehir, 34752  
İstanbul / Turkey  
T +90 216 641 44 24  
F +90 216 641 44 25

### Meril China Co. Ltd.

2301b,23f, Lixin Plaza,  
no 90, South Hubin Road,  
Xiamen, China  
T 0086-592-5368505  
F 0086-592-5368519

### Meril SA Pty. Ltd.

102, 104, S101 and S102,  
Boulevard West Office Park,  
142 Western Service Road,  
Erf 813 Woodmead Extension 17  
Sandton, Johannesburg – 2191  
South Africa  
T +27 11 465-2049  
F +27 86 471 7941

### Meril Medical LLC.

Nauchnyi Proezd 19,  
Moscow, Russia – 117 246.  
Office - +7 495 772 7643

### EU representative.


Obelis S.A.  
Bd. General Wahis 53,  
1030, Brussels, Belgium.  
T +32 2 732 5954  
F +32 2 732 6003  
E mail@obelis.net

E askinfo@merillife.com  
W www.merillife.com



1434

For the use of a Registered Medical Practitioner of Hospital or Laboratory only



**biomimeaura™**  
Sirolimus Eluting Coronary Stent System

65µm Strut Thickness

Biodegradable Polymer Coating

Morphology Mediated Expansion


Advanced Delivery System



BIA/BROCHURE/005/20210205/GLOBAL

# biomimEaura™

## Sirolimus Eluting Coronary Stent System



meriT Trails:  
Consistent clinical safety & efficacy in more than 1650 patients up to 5 years.


meriT-I	meriT-II	meriT-III
<ul style="list-style-type: none"> <li>Single center, FIM</li> <li>30 Patients(30Lesions)</li> <li>8-month angiographic FU</li> <li>2-year clinical FU</li> </ul> <p><b>Key results (1-yr. n=28)</b></p> <ul style="list-style-type: none"> <li>▲ B2/C: 76.7%</li> <li>▲ MACE: 0%</li> <li>▲ TLR: 0%</li> <li>▲ ST: 0%</li> </ul> <p>1-year: Dani S, Costa RA, Joshi H, et al. EuroIntervention 2013;9:493-500</p>	<ul style="list-style-type: none"> <li>Multicenter (11 centers)</li> <li>250 patients(355 lesion)</li> <li>8-month angiographic FU</li> <li>5-year clinical FU</li> </ul> <p><b>Key results (1-yr. n=214)</b></p> <ul style="list-style-type: none"> <li>▲ B2/C: 63.4%</li> <li>▲ MACE: 8.9%</li> <li>▲ TLR: 6.1%</li> <li>▲ ST: 0.5%</li> </ul> <p>1-year: Seth A, Costa RA, Kaul U, et al. AsiaIntervention 2016;2:19-27</p>	<ul style="list-style-type: none"> <li>Multicenter (15 centers)</li> <li>1161 patients( 1312 lesions)</li> <li>Real-world registry</li> <li>1-year clinical FU</li> </ul> <p><b>Key results (1-yr., n=1161)</b></p> <ul style="list-style-type: none"> <li>▲ 41.1% diabetics</li> <li>▲ 52.5 % hypertensive</li> <li>▲ MACE: 2.35%</li> <li>▲ TLR: 0.5%</li> <li>▲ ST: 0.1%</li> </ul> <p>1-year: Jain RK, Chakravarthi P, Shetty R, et al. Indian Heart J 2016;68:599-603</p>

### meriT-V RCT

#### Non-Inferiority of BioMime SES versus XIENCE EES Proven

Prospective | Randomized | Multicenter Trial

12 sites in Europe (Netherlands, Belgium, UK, Spain, Latvia, Macedonia, Czech Republic & Poland) and 3 sites in Brazil



Clinical Outcomes	9-month (n=252)	
	BioMime SES (n=168)	XIENCE SES ( n=84)
<b>MACE</b>	<b>5 (2.98%)</b>	<b>6 (7.14%)</b>
Cardiac Death	0	0
MI	1 (0.60%)	4 (4.76%)
ID-TLR	4 (2.38%)	2 (2.38%)
ID- TVR (non-TLR)	0	0
<b>Stent Thrombosis</b>	<b>0</b>	<b>0</b>

Source : Abizaid AA, Kedev S, Kedhi E, et al. Eurontervention 2018; 14 : 21207-e14.

With BioMime Aura, complex lesions can be treated with high degree of ease, ensuring both acute procedural success and predictive long term clinical safety and efficacy.